Dr. Bonomi Discusses PD-L1 as a Biomarker in NSCLC

Philip D. Bonomi, MD
Published: Friday, Oct 06, 2017



Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non–small cell lung cancer (NSCLC).

Although PD-L1 is not a perfect biomarker, it remains a player in the immunotherapy arena, says Bonomi.

If regimens like combining immunotherapy and chemotherapy demonstrate good results, there may not even be a need for biomarkers, Bonomi adds.
 


Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non–small cell lung cancer (NSCLC).

Although PD-L1 is not a perfect biomarker, it remains a player in the immunotherapy arena, says Bonomi.

If regimens like combining immunotherapy and chemotherapy demonstrate good results, there may not even be a need for biomarkers, Bonomi adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x